TCTC Holdings’s Sarepta Therapeutics SRPT Stock Holding History

TCTC Holdings’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-60	Closed	-$7.77K	–	573
2024 Q1	$7.77K	Buy	+60	New	+$7.35K	﹤0.01%	449

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TCTC Holdings's SRPT Position: Q2 2024 in Review

TCTC Holdings sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 60 shares — an estimated $7.77K sold.

TCTC Holdings first reported a position in SRPT in Q1 2024 and held it in 1 quarter. The position peaked at $7.77K in Q1 2024. 483 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

TCTC Holdings reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
TCTC Holdings sold 60 Sarepta Therapeutics shares in Q2 2024, an estimated $7.77K.
TCTC Holdings first reported a position in Sarepta Therapeutics in Q1 2024 and held it in 1 quarter.
TCTC Holdings's Sarepta Therapeutics position peaked at $7.77K in Q1 2024.
483 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on TCTC Holdings's 13F filing for Q2 2024, filed 6 Aug 2024.